ClinicalTrials.gg
CompletedNCT00600821Updated Nov 8, 2013Results posted

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

A Phase 2 interventional study of Bevacizumab and Carboplatin in Non-Small-Cell Lung Carcinoma and Adenocarcinoma, sponsored by Pfizer. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
53rd of 136
118 · median 79
Started
2008
with 7 others
Phase 2
45 of 158
3 open now
Registered
31st of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 53rd largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2008, is one of 45 in phase 2, and was the 31st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

03

Conditions studied

  • Non-Small-Cell Lung Carcinoma
  • Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced non squamous cell, lung cancer
  • No prior treatment for lung cancer except prior therapy if last dose was >12 months prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for advanced lung cancer
  • The need for blood-thinners
  • Coughing up blood
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Active comparator
    B

    Bevacizumab will be administered in combination with carboplatin and paclitaxel.

    Drug: Bevacizumab · Drug: Carboplatin · Drug: Paclitaxel

  • Experimental
    A

    AG-013736 will be administered in combination with carboplatin and paclitaxel.

    Drug: AG-013736 (axitinib) · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.

    Also known as: Avastin

  • Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.

  • Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks

  • AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-

    Also known as: axitinib Taxol

  • Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\*min/ml, iv infusion, every 3 weeks.

  • Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years

Secondary outcomes

  1. Overall Survival (OS)

    Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)

  2. Percentage of Participants With Objective Response (OR)

    OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.

    Time frame: Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years

  3. Duration of Response (DR)

    Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years

  4. Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1

  5. European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

    Time frame: Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)

  6. European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score

    QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

    Time frame: Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)

  7. Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood

    RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.

    Time frame: Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1

  8. Circulating Endothelial Cells (CEC) in Blood: Total CEC

    Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.

    Time frame: Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1

  9. Circulating Endothelial Cells (CEC) in Blood

    Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.

    Time frame: Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1

  10. Plasma Concentration of Soluble Proteins

    Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor \[VEGF\], and vascular endothelial growth factor receptor-2 \[VEGFR2\], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.

    Time frame: Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1

Other outcomes

  1. Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype

    UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.

    Time frame: Baseline (Day 1 of Cycle 1)

07

Results

Posted May 22, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Started5860
Treated5859
Completed00
Not completed5860
Withdrew: Death4546
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject11
Withdrew: Terminated by sponsor86
Withdrew: Objective progression or relapse01
Withdrew: Randomized but not treated01
Withdrew: Other23

Outcome measures

PrimaryProgression Free Survival (PFS)

Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Progression Free Survival (PFS)5.7 (4.1 to 7.5)6.1 (4.2 to 8.7)
Statistical analysis
  • Axitinib + Paclitaxel + Carboplatin vs Bevacizumab + Paclitaxel + Carboplatin · Log Rank · p = 0.639 (One-sided log-rank test at alpha = 0.20 significance level was used.) · Hazard ratio (hr): 1.093 · 95% CI 0.679 to 1.761
SecondaryOverall Survival (OS)

Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Overall Survival (OS)10.6 (7.5 to 16.4)13.3 (10.4 to 17.6)
Statistical analysis
  • Axitinib + Paclitaxel + Carboplatin vs Bevacizumab + Paclitaxel + Carboplatin · Log Rank · p = 0.699 (One-sided log-rank test at alpha = 0.20 significance level was used.) · Hazard ratio (hr): 1.117 · 95% CI 0.739 to 1.689
SecondaryPercentage of Participants With Objective Response (OR)

OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.

Time frame:
Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Percentage of Participants With Objective Response (OR)29.3 (18.1 to 42.7)43.3 (30.6 to 56.8)
Statistical analysis
  • Axitinib + Paclitaxel + Carboplatin vs Bevacizumab + Paclitaxel + Carboplatin · Cochran-Mantel-Haenszel · p = 0.9422 · Risk ratio (rr): 0.676 · 95% CI 0.412 to 1.107
SecondaryDuration of Response (DR)

Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years
Reported as:
Median · Months
Duration of Response (DR)
MonthsAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Duration of Response (DR)4.4 (4.2 to 6.7)7.0 (4.8 to 8.3)
SecondaryPopulation Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1

Results for this outcome have not been posted.

SecondaryEuropean Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

Time frame:
Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)
Reported as:
Mean · Units on a scale
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Units on a scaleAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Physical functioning (PF): Baseline (n=58, 59)66.29 ± 22.0475.00 ± 22.21
PF: C2 D1 (n=51, 53)67.45 ± 23.4875.47 ± 20.24
PF: C3 D1 (n=45, 47)65.78 ± 24.4078.16 ± 18.43
PF: C4 D1 (n=37, 48)67.88 ± 20.0173.78 ± 19.14
PF: C5 D1 (n=34, 38)61.18 ± 24.0975.09 ± 16.38
PF: C6 D1 (n=31, 33)65.86 ± 19.1773.94 ± 18.66
PF: C7 D1 (n=27, 30)66.42 ± 22.1574.89 ± 18.67
PF: C8 D1 (n=22, 28)67.27 ± 22.4477.14 ± 18.98
PF: C9 D1 (n=18, 23)66.30 ± 27.7774.57 ± 19.02
PF: C10 D1 (n=17, 20)68.63 ± 25.3681.33 ± 14.92
PF: C11 D1 (n=15, 19)60.67 ± 23.5878.25 ± 16.00
PF: C12 D1 (n=10, 17)71.33 ± 20.8678.43 ± 19.65
PF: C13 D1 (n=8, 14)66.67 ± 25.9479.05 ± 21.22
PF: End of treatment (EOT) (n=27, 38)62.96 ± 21.1164.91 ± 24.83
Role functioning: Baseline (n=58, 58)60.92 ± 31.1560.63 ± 31.79
Role functioning: C2 D1 (n=51, 53)64.38 ± 31.9865.41 ± 29.02
Role functioning: C3 D1 (n=45, 47)58.15 ± 34.0170.92 ± 28.55
Role functioning: C4 D1 (n=37, 48)67.12 ± 26.4967.36 ± 25.02
Role functioning: C5 D1 (n=34, 38)57.35 ± 29.6466.23 ± 29.12
Role functioning: C6 D1 (n=31, 33)62.90 ± 30.3467.68 ± 29.15
Role functioning: C7 D1 (n=28, 30)55.36 ± 32.4163.89 ± 27.01
Role functioning: C8 D1 (n=22, 28)65.15 ± 29.0571.43 ± 19.70
Role functioning: C9 D1 (n=18, 23)63.89 ± 37.6070.29 ± 18.77
Role functioning: C10 D1 (n=17, 20)66.67 ± 28.8770.83 ± 20.14
Role functioning: C11 D1 (n=15, 19)60.00 ± 29.4171.93 ± 21.55
Role functioning: C12 D1 (n=10, 17)75.00 ± 21.1570.59 ± 21.67
Role functioning: C13 D1 (n=8, 14)62.50 ± 33.0480.95 ± 20.52
Role functioning: EOT (n=27, 38)57.41 ± 32.4757.90 ± 31.18
Emotional functioning: Baseline (n=57, 57)69.74 ± 23.4563.74 ± 27.44
Emotional functioning: C2 D1 (n=50, 53)78.33 ± 21.7673.64 ± 22.81
Emotional functioning: C3 D1 (n=45, 48)75.19 ± 21.3678.76 ± 20.69
Emotional functioning: C4 D1 (n=37, 48)75.75 ± 20.1776.04 ± 23.23
Emotional functioning: C5 D1 (n=32, 38)77.60 ± 18.3878.51 ± 21.37
Emotional functioning: C6 D1 (n=29, 32)78.74 ± 18.9777.35 ± 23.40
Emotional functioning: C7 D1 (n=28, 30)78.57 ± 22.6279.45 ± 20.50
Emotional functioning: C8 D1 (n=22, 28)77.65 ± 19.1481.25 ± 18.09
Emotional functioning: C9 D1 (n=18, 23)74.07 ± 19.7878.50 ± 23.39
Emotional functioning: C10 D1 (n=17, 20)77.94 ± 18.8578.33 ± 13.36
Emotional functioning: C11 D1 (n=15, 19)70.00 ± 21.3282.46 ± 18.61
Emotional functioning: C12 D1 (n=10, 17)74.17 ± 27.9077.45 ± 20.57
Emotional functioning: C13 D1 (n=8, 14)77.08 ± 22.6083.93 ± 14.79
Emotional functioning: EOT (n=27, 38)68.52 ± 26.3970.18 ± 25.60
Cognitive Functioning: Baseline (n=57, 57)80.12 ± 24.2883.33 ± 19.16
Cognitive Functioning: C2 D1 (n=50, 53)84.00 ± 20.4784.28 ± 21.29
Cognitive Functioning: C3 D1 (n=45, 48)85.19 ± 22.8185.42 ± 20.81
Cognitive Functioning: C4 D1 (n=37, 48)84.68 ± 18.9982.64 ± 20.03
Cognitive Functioning: C5 D1 (n=32, 38)84.37 ± 19.8383.33 ± 24.51
Cognitive Functioning: C6 D1 (n=29, 32)86.78 ± 18.0381.25 ± 21.06
Cognitive Functioning: C7 D1 (n=28, 30)79.76 ± 19.4385.56 ± 18.94
Cognitive Functioning: C8 D1 (n=22, 28)89.39 ± 17.4888.69 ± 17.00
Cognitive Functioning: C9 D1 (n=18, 23)84.26 ± 15.6386.23 ± 20.51
Cognitive Functioning: C10 D1 (n=17, 20)88.23 ± 12.8690.00 ± 13.68
Cognitive Functioning: C11 D1 (n=15, 19)82.22 ± 18.3385.96 ± 18.64
Cognitive Functioning: C12 D1 (n=10, 17)90.00 ± 14.0587.25 ± 20.01
Cognitive Functioning: C13 D1 (n=8, 14)85.42 ± 13.9195.24 ± 12.10
Cognitive Functioning: EOT (n=27, 38)77.78 ± 23.5778.95 ± 22.82
Social functioning: Baseline (n=57, 57)71.35 ± 27.5965.50 ± 32.25
Social functioning: C2 D1 (n=50, 52)69.67 ± 30.0675.32 ± 25.24
Social functioning: C3 D1 (n=45, 48)71.11 ± 27.6274.65 ± 24.79
Social functioning: C4 D1 (n=37, 48)73.42 ± 24.9971.53 ± 29.77
Social functioning: C5 D1 (n=32, 38)65.10 ± 26.2275.88 ± 27.04
Social functioning: C6 D1 (n=29, 32)70.11 ± 26.4971.88 ± 26.92
Social functioning: C7 D1 (n=28, 30)64.88 ± 32.5072.22 ± 23.71
Social functioning: C8 D1 (n=22, 28)71.97 ± 24.8772.02 ± 24.45
Social functioning: C9 D1 (n=18, 23)74.07 ± 29.8381.16 ± 16.13
Social functioning: C10 D1 (n=17, 20)72.55 ± 32.2479.17 ± 20.14
Social functioning: C11 D1 (n=15, 19)66.67 ± 28.1778.95 ± 16.52
Social functioning: C12 D1 (n=10, 17)71.67 ± 20.8680.39 ± 20.61
Social functioning: C13 D1 (n=8, 14)56.25 ± 28.0880.95 ± 18.32
Social functioning: EOT (n=27, 38)69.14 ± 26.0365.79 ± 26.83
Fatigue: Baseline (n=57, 58)40.45 ± 23.9438.89 ± 28.02
Fatigue: C2 D1 (n=51, 53)43.57 ± 21.9836.48 ± 25.26
Fatigue: C3 D1 (n=45, 47)47.41 ± 22.7733.80 ± 19.38
Fatigue: C4 D1 (n=37, 48)42.34 ± 19.2237.85 ± 19.40
Fatigue: C5 D1 (n=34, 38)44.61 ± 21.7336.84 ± 22.83
Fatigue: C6 D1 (n=31, 33)45.16 ± 23.6533.50 ± 21.45
Fatigue: C7 D1 (n=28, 30)47.82 ± 27.2740.74 ± 21.11
Fatigue: C8 D1 (n=22, 28)44.95 ± 24.8432.14 ± 20.14
Fatigue: C9 D1 (n=18, 23)40.12 ± 29.8028.98 ± 20.03
Fatigue: C10 D1 (n=17, 20)41.83 ± 25.6230.00 ± 19.78
Fatigue: C11 D1 (n=15, 19)47.78 ± 32.5228.07 ± 14.52
Fatigue: C12 D1 (n=10, 17)37.78 ± 19.7429.41 ± 18.82
Fatigue: C13 D1 (n=8, 14)50.00 ± 24.4926.19 ± 22.05
Fatigue: EOT (n=27, 38)51.03 ± 24.5143.13 ± 27.57
Nausea and vomiting: Baseline (n=57, 59)8.77 ± 17.859.89 ± 21.91
Nausea and vomiting: C2 D1 (n=51, 53)7.19 ± 13.025.35 ± 12.56
Nausea and vomiting: C3 D1 (n=45, 47)11.11 ± 17.775.67 ± 11.67
Nausea and vomiting: C4 D1 (n=37, 48)10.81 ± 16.777.29 ± 11.86
Nausea and vomiting: C5 D1 (n=34, 38)13.24 ± 21.637.46 ± 14.34
Nausea and vomiting: C6 D1 (n=31, 33)13.44 ± 21.2610.61 ± 17.59
Nausea and vomiting: C7 D1 (n=28, 30)15.48 ± 22.659.44 ± 14.31
Nausea and vomiting: C8 D1 (n=22, 28)14.40 ± 22.005.95 ± 12.18
Nausea and vomiting: C9 D1 (n=18, 23)9.26 ± 13.065.07 ± 20.98
Nausea and vomiting: C10 D1 (n=17, 20)11.77 ± 15.338.33 ± 16.67
Nausea and vomiting: C11 D1 (n=15, 19)14.45 ± 17.675.26 ± 9.71
Nausea and vomiting: C12 D1 (n=10, 17)15.00 ± 16.576.68 ± 14.50
Nausea and vomiting: C13 D1 (n=8, 14)12.50 ± 17.255.95 ± 14.03
Nausea and vomiting: EOT (n=27, 38)16.05 ± 22.407.90 ± 14.36
Pain: Baseline (n=57, 59)31.29 ± 31.8235.31 ± 30.02
Pain: C2 D1 (n=51, 53)29.74 ± 29.8728.30 ± 29.16
Pain: C3 D1 (n=45, 48)30.00 ± 27.4318.75 ± 18.07
Pain: C4 D1 (n=37, 48)26.58 ± 18.6225.35 ± 27.29
Pain: C5 D1 (n=34, 38)25.00 ± 18.9124.12 ± 24.72
Pain: C6 D1 (n=31, 33)31.18 ± 18.6325.25 ± 28.90
Pain: C7 D1 (n=28, 30)28.57 ± 28.9927.22 ± 26.07
Pain: C8 D1 (n=22, 28)28.03 ± 25.9122.62 ± 23.66
Pain: C9 D1 (n=18, 23)33.33 ± 22.1427.54 ± 31.22
Pain: C10 D1 (n=17, 20)30.39 ± 26.5124.17 ± 24.47
Pain: C11 D1 (n=15, 19)43.33 ± 28.0318.42 ± 21.44
Pain: C12 D1 (n=10, 17)35.00 ± 21.4523.53 ± 29.50
Pain: C13 D1 (n=8, 14)35.42 ± 24.3016.67 ± 21.68
Pain: EOT (n=27, 38)38.27 ± 33.2734.65 ± 30.36
Dyspnoea: Baseline (n=56, 58)32.74 ± 30.1536.21 ± 33.21
Dyspnoea: C2 D1 (n=51, 52)32.03 ± 28.2524.36 ± 31.04
Dyspnoea: C3 D1 (n=45, 47)38.52 ± 28.3919.15 ± 23.82
Dyspnoea: C4 D1 (n=37, 48)33.33 ± 30.4321.53 ± 25.25
Dyspnoea: C5 D1 (n=34, 38)36.27 ± 33.2023.68 ± 27.84
Dyspnoea: C6 D1 (n=31, 33)36.56 ± 31.4520.20 ± 23.48
Dyspnoea: C7 D1 (n=28, 30)38.09 ± 31.0521.11 ± 20.50
Dyspnoea: C8 D1 (n=22, 28)27.27 ± 28.4316.67 ± 19.24
Dyspnoea: C9 D1 (n=18, 23)25.93 ± 33.4421.74 ± 21.58
Dyspnoea: C10 D1 (n=17, 20)27.45 ± 31.7018.33 ± 17.01
Dyspnoea: C11 D1 (n=15, 19)37.78 ± 33.0117.54 ± 23.22
Dyspnoea: C12 D1 (n=10, 17)23.33 ± 27.4421.57 ± 23.40
Dyspnoea: C13 D1 (n=8, 14)37.50 ± 37.5319.05 ± 17.12
Dyspnoea: EOT (n=27, 38)35.80 ± 27.6233.33 ± 33.78
Insomnia: Baseline (n=57, 58)46.20 ± 33.1937.93 ± 31.50
Insomnia: C2 D1 (n=51, 53)36.60 ± 36.0628.30 ± 33.59
Insomnia: C3 D1 (n=45, 47)30.37 ± 33.2029.08 ± 33.06
Insomnia: C4 D1 (n=37, 48)24.32 ± 26.8127.08 ± 28.89
Insomnia: C5 D1 (n=34, 38)28.43 ± 24.8023.68 ± 31.87
Insomnia: C6 D1 (n=31, 33)24.73 ± 25.7724.24 ± 29.19
Insomnia: C7 D1 (n=28, 30)23.81 ± 28.4825.55 ± 24.26
Insomnia: C8 D1 (n=22, 28)21.21 ± 26.3219.05 ± 23.00
Insomnia: C9 D1 (n=18, 23)25.93 ± 31.4323.19 ± 27.40
Insomnia: C10 D1 (n=17, 20)27.45 ± 26.9720.00 ± 25.13
Insomnia: C11 D1 (n=15, 19)33.33 ± 28.1722.81 ± 24.97
Insomnia: C12 D1 (n=10, 17)26.67 ± 21.0823.53 ± 28.30
Insomnia: C13 D1 (n=8, 14)12.50 ± 17.2516.67 ± 17.29
Insomnia: EOT (n=27, 37)28.39 ± 27.2836.94 ± 30.21
Loss of appetite: Baseline (n=57, 59)29.82 ± 28.6531.64 ± 34.14
Loss of appetite: C2 D1 (n=51, 53)23.53 ± 26.9120.75 ± 29.40
Loss of appetite: C3 D1 (n=44, 47)33.33 ± 32.9417.02 ± 25.89
Loss of appetite: C4 D1 (n=37, 48)26.13 ± 26.2223.61 ± 27.47
Loss of appetite: C5 D1 (n=34, 38)30.39 ± 33.2021.05 ± 29.43
Loss of appetite: C6 D1 (n=31, 33)27.96 ± 31.1523.23 ± 26.98
Loss of appetite: C7 D1 (n=28, 30)39.29 ± 34.0124.44 ± 23.05
Loss of appetite: C8 D1 (n=22, 28)36.36 ± 28.9319.05 ± 21.14
Loss of appetite: C9 D1 (n=18, 23)31.48 ± 26.7513.04 ± 24.08
Loss of appetite: C10 D1 (n=17, 20)39.22 ± 31.7020.00 ± 25.13
Loss of appetite: C11 D1 (n=15, 19)33.33 ± 35.6415.79 ± 17.10
Loss of appetite: C12 D1 (n=10, 17)16.67 ± 23.5723.53 ± 30.65
Loss of appetite: C13 D1 (n=8, 14)29.17 ± 21.3616.67 ± 28.49
Loss of appetite: EOT (n=27, 38)39.51 ± 34.6437.72 ± 33.93
Constipation: Baseline (n=56, 57)15.48 ± 23.7521.05 ± 31.89
Constipation: C2 D1 (n=50, 53)21.33 ± 28.3820.13 ± 26.43
Constipation: C3 D1 (n=45, 47)18.52 ± 24.1614.89 ± 23.88
Constipation: C4 D1 (n=36, 48)18.52 ± 26.9613.19 ± 21.46
Constipation: C5 D1 (n=32, 38)18.75 ± 22.3021.05 ± 27.31
Constipation: C6 D1 (n=28, 33)22.62 ± 25.7519.19 ± 28.90
Constipation: C7 D1 (n=28, 30)25.00 ± 26.647.78 ± 14.34
Constipation: C8 D1 (n=22, 28)19.70 ± 19.682.38 ± 8.74
Constipation: C9 D1 (n=18, 23)9.26 ± 19.155.80 ± 12.92
Constipation: C10 D1 (n=17, 20)17.65 ± 20.815.00 ± 12.21
Constipation: C11 D1 (n=15, 19)22.22 ± 20.578.77 ± 18.73
Constipation: C12 D1 (n=10, 17)20.00 ± 23.315.88 ± 17.62
Constipation: C13 D1 (n=8, 14)16.67 ± 25.204.76 ± 12.10
Constipation: EOT (n=27, 38)20.99 ± 29.4514.03 ± 24.05
Diarrhoea: Baseline (n=55, 57)6.67 ± 17.455.85 ± 14.26
Diarrhoea: C2 D1 (n=50, 53)11.33 ± 17.3110.06 ± 21.27
Diarrhoea: C3 D1 (n=45, 48)15.55 ± 18.269.72 ± 21.70
Diarrhoea: C4 D1 (n=37, 47)13.51 ± 19.975.67 ± 12.66
Diarrhoea: C5 D1 (n=32, 38)22.92 ± 32.177.89 ± 18.07
Diarrhoea: C6 D1 (n=29, 32)21.84 ± 28.5610.42 ± 19.74
Diarrhoea: C7 D1 (n=28, 30)16.67 ± 26.4511.11 ± 15.98
Diarrhoea: C8 D1 (n=22, 28)24.24 ± 31.174.76 ± 11.88
Diarrhoea: C9 D1 (n=18, 23)27.78 ± 28.585.80 ± 12.92
Diarrhoea: C10 D1 (n=17, 20)23.53 ± 30.6510.00 ± 19.04
Diarrhoea: C11 D1 (n=15, 19)31.11 ± 34.430.00 ± 0.00
Diarrhoea: C12 D1 (n=10, 17)43.33 ± 16.100.00 ± 0.00
Diarrhoea: C13 D1 (n=8, 14)33.33 ± 25.207.14 ± 14.19
Diarrhoea: EOT (n=27, 38)23.46 ± 28.963.51 ± 12.94
Financial difficulties: Baseline (n=56, 57)22.62 ± 31.8521.64 ± 27.09
Financial difficulties: C2 D1 (n=49, 53)21.77 ± 31.5920.12 ± 27.22
Financial difficulties: C3 D1 (n=45, 48)25.93 ± 30.8918.05 ± 23.78
Financial difficulties: C4 D1 (n=37, 48)21.62 ± 27.4620.83 ± 30.46
Financial difficulties: C5 D1 (n=32, 38)26.04 ± 30.2121.05 ± 28.39
Financial difficulties: C6 D1 (n=29, 32)26.44 ± 28.7020.83 ± 29.02
Financial difficulties: C7 D1 (n=28, 30)26.19 ± 31.8926.67 ± 30.83
Financial difficulties: C8 D1 (n=21, 28)28.57 ± 35.4121.43 ± 32.98
Financial difficulties: C9 D1 (n=18, 23)27.78 ± 36.6017.39 ± 29.93
Financial difficulties: C10 D1 (n=17, 19)27.45 ± 33.8224.56 ± 33.04
Financial difficulties: C11 D1 (n=15, 19)20.00 ± 30.3419.30 ± 27.92
Financial difficulties: C12 D1 (n=10, 17)13.33 ± 23.3117.65 ± 26.66
Financial difficulties: C13 D1 (n=8, 14)20.83 ± 35.3616.67 ± 28.49
Financial difficulties: EOT (n=27, 37)23.46 ± 27.4528.83 ± 32.55
Global health status/QoL: Baseline (n=57, 57)53.22 ± 22.0354.97 ± 21.06
Global health status/QoL: C2 D1 (n=49, 53)58.16 ± 20.3859.59 ± 17.78
Global health status/QoL: C3 D1 (n=45, 48)56.67 ± 20.0759.72 ± 16.34
Global health status/QoL: C4 D1 (n=37, 47)57.21 ± 18.0257.80 ± 18.17
Global health status/QoL: C5 D1 (n=32, 38)58.07 ± 21.9461.84 ± 17.61
Global health status/QoL: C6 D1 (n=29, 32)53.45 ± 17.7560.94 ± 17.51
Global health status/QoL: C7 D1 (n=28, 30)55.65 ± 20.1758.61 ± 15.39
Global health status/QoL: C8 D1 (n=22, 28)56.82 ± 17.1860.71 ± 15.36
Global health status/QoL: C9 D1 (n=18, 22)56.48 ± 23.1464.40 ± 15.89
Global health status/QoL: C10 D1 (n=17, 20)55.39 ± 17.9162.50 ± 14.93
Global health status/QoL: C11 D1 (n=15, 19)47.78 ± 19.0263.60 ± 15.52
Global health status/QoL: C12 D1 (n=10, 17)54.17 ± 19.3563.73 ± 12.48
Global health status/QoL: C13 D1 (n=8, 14)53.13 ± 19.8958.33 ± 15.68
Global health status/QoL: EOT (n=27, 38)49.38 ± 20.9250.22 ± 21.62
SecondaryEuropean Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score

QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.

Time frame:
Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)
Reported as:
Mean · Units on a scale
European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score
Units on a scaleAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cough: Baseline (n=56, 59)37.50 ± 31.1838.42 ± 24.62
Cough: C2 D1 (n=50, 53)30.67 ± 24.1330.19 ± 20.94
Cough: C3 D1 (n=46, 47)28.98 ± 25.9228.37 ± 23.03
Cough: C4 D1 (n=37, 48)29.73 ± 25.8027.08 ± 20.23
Cough: C5 D1 (n=33, 38)22.22 ± 18.0028.07 ± 23.92
Cough: C6 D1 (n=29, 33)26.44 ± 24.2026.26 ± 23.21
Cough: C7 D1 (n=28, 29)25.00 ± 21.5225.29 ± 24.65
Cough: C8 D1 (n=22, 27)21.21 ± 19.3719.75 ± 21.20
Cough: C9 D1 (n=18, 23)20.37 ± 20.2624.64 ± 25.06
Cough: C10 D1 (n=17, 20)23.53 ± 25.7321.67 ± 22.36
Cough: C11 D1 (n=15, 19)24.44 ± 23.4626.31 ± 23.78
Cough: C12 D1 (n=10, 17)26.66 ± 14.0529.41 ± 30.92
Cough: C13 D1 (n=8, 14)33.33 ± 25.2021.43 ± 21.11
Cough: End of treatment (EOT) (n=26, 38)33.33 ± 21.0833.33 ± 29.00
Haemoptysis: Baseline (n=56, 59)2.98 ± 11.513.39 ± 10.16
Haemoptysis: C2 D1 (n=50, 53)2.67 ± 9.131.89 ± 7.78
Haemoptysis: C3 D1 (n=44, 47)0.76 ± 5.025.67 ± 14.44
Haemoptysis: C4 D1 (n=36, 48)0.93 ± 5.563.47 ± 10.29
Haemoptysis: C5 D1 (n=33, 38)1.01 ± 5.803.51 ± 12.94
Haemoptysis: C6 D1 (n=29, 33)3.45 ± 13.643.03 ± 12.81
Haemoptysis: C7 D1 (n=27, 29)0.00 ± 0.003.45 ± 10.33
Haemoptysis: C8 D1 (n=22, 27)0.00 ± 0.001.23 ± 6.41
Haemoptysis: C9 D1 (n=18, 23)0.00 ± 0.000.00 ± 0.00
Haemoptysis: C10 D1 (n=17, 20)0.00 ± 0.000.00 ± 0.00
Haemoptysis: C11 D1 (n=15, 19)0.00 ± 0.000.00 ± 0.00
Haemoptysis: C12 D1 (n=10, 17)0.00 ± 0.000.00 ± 0.00
Haemoptysis: C13 D1 (n=8, 14)4.17 ± 11.780.00 ± 0.00
Haemoptysis: EOT (n=26, 38)0.00 ± 0.005.26 ± 16.49
Dyspnoea: Baseline (n=56, 58)29.17 ± 20.6031.42 ± 28.85
Dyspnoea: C2 D1 (n=48, 53)29.86 ± 25.2323.90 ± 21.51
Dyspnoea: C3 D1 (n=45, 43)33.83 ± 22.0920.41 ± 18.61
Dyspnoea: C4 D1 (n=36, 45)32.10 ± 20.0124.69 ± 21.57
Dyspnoea: C5 D1 (n=33, 37)30.30 ± 21.2123.12 ± 19.84
Dyspnoea: C6 D1 (n=28, 31)35.32 ± 24.7621.86 ± 18.70
Dyspnoea: C7 D1 (n=27, 27)30.45 ± 25.5220.16 ± 16.02
Dyspnoea: C8 D1 (n=22, 26)24.75 ± 21.9421.37 ± 16.61
Dyspnoea: C9 D1 (n=18, 22)27.78 ± 29.8318.69 ± 14.70
Dyspnoea: C10 D1 (n=17, 19)28.76 ± 27.8019.88 ± 15.08
Dyspnoea: C11 D1 (n=15, 18)27.41 ± 24.8019.75 ± 15.51
Dyspnoea: C12 D1 (n=10, 17)23.33 ± 22.5022.22 ± 19.25
Dyspnoea: C13 D1 (n=8, 14)37.50 ± 31.9516.67 ± 16.16
Dyspnoea: EOT (n=25, 37)34.22 ± 23.3333.63 ± 28.39
Sore Mouth: Baseline (n=56, 58)3.57 ± 12.191.15 ± 6.13
Sore Mouth: C2 D1 (n=51, 53)18.95 ± 26.889.43 ± 23.00
Sore Mouth: C3 D1 (n=45, 47)18.52 ± 28.039.22 ± 21.65
Sore Mouth: C4 D1 (n=37, 48)21.62 ± 31.648.33 ± 21.19
Sore Mouth: C5 D1 (n=33, 38)23.23 ± 36.7911.40 ± 23.60
Sore Mouth: C6 D1 (n=28, 33)16.67 ± 30.776.06 ± 19.46
Sore Mouth: C7 D1 (n=28, 29)17.86 ± 27.946.90 ± 16.38
Sore Mouth: C8 D1 (n=22, 27)16.67 ± 30.433.70 ± 10.67
Sore Mouth: C9 D1 (n=18, 23)9.26 ± 15.365.80 ± 16.37
Sore Mouth: C10 D1 (n=17, 20)19.61 ± 33.4610.00 ± 26.71
Sore Mouth: C11 D1 (n=15, 19)22.22 ± 37.098.77 ± 24.45
Sore Mouth: C12 D1 (n=10, 17)16.67 ± 23.577.84 ± 18.74
Sore Mouth: C13 D1 (n=8, 14)25.00 ± 38.834.76 ± 12.10
Sore Mouth: EOT (n=26, 38)8.97 ± 24.144.39 ± 13.80
Dysphagia: Baseline (n=56, 59)6.55 ± 17.316.78 ± 14.88
Dysphagia: C2 D1 (n=51, 53)11.76 ± 22.926.92 ± 17.73
Dysphagia: C3 D1 (n=46, 47)13.77 ± 20.584.96 ± 11.99
Dysphagia: C4 D1 (n=37, 48)9.91 ± 20.592.78 ± 9.31
Dysphagia: C5 D1 (n=32, 38)12.50 ± 26.444.39 ± 11.42
Dysphagia: C6 D1 (n=28, 33)13.10 ± 27.737.07 ± 16.15
Dysphagia: C7 D1 (n=28, 28)11.90 ± 26.005.95 ± 15.85
Dysphagia: C8 D1 (n=22, 27)16.67 ± 26.731.23 ± 6.41
Dysphagia: C9 D1 (n=18, 23)9.26 ± 15.361.45 ± 6.95
Dysphagia: C10 D1 (n=17, 20)21.57 ± 26.206.67 ± 17.44
Dysphagia: C11 D1 (n=15, 19)24.44 ± 29.461.75 ± 7.65
Dysphagia: C12 D1 (n=10, 17)6.67 ± 14.053.92 ± 16.17
Dysphagia: C13 D1 (n=8, 14)20.83 ± 24.804.76 ± 17.82
Dysphagia: EOT (n=26, 38)7.69 ± 21.727.89 ± 19.66
Peripheral neuropathy: Baseline (n=56, 59)9.52 ± 19.8115.25 ± 26.50
Peripheral neuropathy: C2 D1 (n=51, 53)24.84 ± 30.4433.96 ± 33.01
Peripheral neuropathy: C3 D1 (n=46, 47)37.68 ± 34.1534.75 ± 36.09
Peripheral neuropathy: C4 D1 (n=37, 48)45.05 ± 37.8638.19 ± 32.97
Peripheral neuropathy: C5 D1 (n=33, 38)50.51 ± 39.1942.11 ± 33.50
Peripheral neuropathy: C6 D1 (n=29, 33)55.17 ± 39.1152.53 ± 33.37
Peripheral neuropathy: C7 D1 (n=28, 29)48.81 ± 37.9354.02 ± 33.82
Peripheral neuropathy: C8 D1 (n=22, 27)57.58 ± 40.0850.62 ± 36.25
Peripheral neuropathy: C9 D1 (n=17, 23)45.10 ± 40.7356.52 ± 36.84
Peripheral neuropathy: C10 D1 (n=17, 20)45.10 ± 42.4048.33 ± 38.20
Peripheral neuropathy: C11 D1 (n=14, 19)50.00 ± 42.8749.12 ± 35.78
Peripheral neuropathy: C12 D1 (n=9, 17)55.56 ± 40.8354.90 ± 38.98
Peripheral neuropathy: C13 D1 (n=8, 14)58.33 ± 42.7347.62 ± 38.60
Peripheral neuropathy: EOT (n=25, 38)37.33 ± 35.1240.35 ± 38.87
Alopecia: Baseline (n=56, 59)2.98 ± 11.512.26 ± 10.48
Alopecia: C2 D1 (n=50, 53)69.33 ± 33.5671.70 ± 32.29
Alopecia: C3 D1 (n=46, 45)73.91 ± 37.1368.89 ± 38.53
Alopecia: C4 D1 (n=37, 45)65.77 ± 40.4360.00 ± 42.40
Alopecia: C5 D1 (n=33, 35)61.62 ± 44.1964.76 ± 44.24
Alopecia: C6 D1 (n=28, 32)69.05 ± 42.4861.46 ± 45.68
Alopecia: C7 D1 (n=28, 28)39.29 ± 46.3140.48 ± 45.68
Alopecia: C8 D1 (n=21, 27)42.86 ± 44.9044.44 ± 48.92
Alopecia: C9 D1 (n=18, 23)27.78 ± 43.1631.88 ± 44.36
Alopecia: C10 D1 (n=17, 20)31.37 ± 43.2511.67 ± 29.17
Alopecia: C11 D1 (n=14, 18)16.67 ± 36.4016.67 ± 34.77
Alopecia: C12 D1 (n=10, 17)13.33 ± 28.119.80 ± 28.30
Alopecia: C13 D1 (n=8, 14)8.33 ± 23.577.14 ± 26.73
Alopecia: EOT (n=26, 37)33.33 ± 42.1627.03 ± 39.94
Chest pain: Baseline (n=56, 59)23.81 ± 28.9320.90 ± 25.45
Chest pain: C2 D1 (n=51, 53)18.95 ± 27.6910.06 ± 18.00
Chest pain: C3 D1 (n=45, 47)14.81 ± 25.185.67 ± 12.66
Chest pain: C4 D1 (n=36, 48)14.81 ± 24.499.03 ± 19.13
Chest pain: C5 D1 (n=33, 38)11.11 ± 19.843.51 ± 10.37
Chest pain: C6 D1 (n=28, 33)15.48 ± 21.241.01 ± 5.80
Chest pain: C7 D1 (n=28, 28)11.90 ± 18.623.57 ± 10.50
Chest pain: C8 D1 (n=22, 27)13.64 ± 16.773.70 ± 10.67
Chest pain: C9 D1 (n=18, 23)12.96 ± 20.267.25 ± 14.06
Chest pain: C10 D1 (n=17, 20)13.72 ± 16.918.33 ± 18.34
Chest pain: C11 D1 (n=15, 19)24.44 ± 29.467.02 ± 13.96
Chest pain: C12 D1 (n=10, 16)13.33 ± 17.212.08 ± 8.33
Chest pain: C13 D1 (n=7, 14)19.05 ± 26.234.76 ± 12.10
Chest pain: EOT (n=26, 37)30.77 ± 33.8915.31 ± 24.34
Arm/shoulder pain: Baseline (n=56, 59)20.83 ± 27.3920.34 ± 29.04
Arm/shoulder pain: C2 D1 (n=51, 53)20.91 ± 28.2520.75 ± 24.66
Arm/shoulder pain: C3 D1 (n=45, 47)14.81 ± 25.185.67 ± 12.66
Arm/shoulder pain: C4 D1 (n=37, 47)18.92 ± 25.5117.02 ± 30.19
Arm/shoulder pain: C5 D1 (n=33, 38)14.14 ± 26.3914.91 ± 26.51
Arm/shoulder pain: C6 D1 (n=29, 33)16.09 ± 26.165.05 ± 12.14
Arm/shoulder pain: C7 D1 (n=28, 29)15.48 ± 23.1014.94 ± 22.86
Arm/shoulder pain: C8 D1 (n=22, 26)16.67 ± 26.7314.10 ± 19.26
Arm/shoulder pain: C9 D1 (n=18, 23)14.81 ± 23.4913.04 ± 19.43
Arm/shoulder pain: C10 D1 (n=17, 20)13.73 ± 23.7420.00 ± 27.36
Arm/shoulder pain: C11 D1 (n=14, 19)26.19 ± 29.7515.79 ± 23.22
Arm/shoulder pain: C12 D1 (n=10, 17)23.33 ± 22.5025.49 ± 32.34
Arm/shoulder pain: C13 D1 (n=8, 14)20.83 ± 24.8019.05 ± 25.20
Arm/shoulder pain: EOT (n=26, 38)21.80 ± 33.9223.68 ± 31.87
Other pain: Baseline (n=52, 57)28.85 ± 32.3625.15 ± 34.09
Other pain: C2 D1 (n=49, 50)26.53 ± 28.8532.67 ± 31.94
Other pain: C3 D1 (n=46, 47)34.06 ± 31.8123.40 ± 31.79
Other pain: C4 D1 (n=36, 45)25.93 ± 27.7328.15 ± 30.11
Other pain: C5 D1 (n=32, 38)25.00 ± 29.3326.32 ± 33.02
Other pain: C6 D1 (n=28, 33)29.76 ± 26.2027.27 ± 33.80
Other pain: C7 D1 (n=28, 28)32.14 ± 35.7035.71 ± 36.21
Other pain: C8 D1 (n=22, 26)16.67 ± 28.6425.64 ± 33.08
Other pain: C9 D1 (n=15, 23)31.11 ± 34.4331.88 ± 34.05
Other pain: C10 D1 (n=16, 19)25.00 ± 28.5522.81 ± 31.53
Other pain: C11 D1 (n=14, 18)42.86 ± 33.1525.93 ± 33.44
Other pain: C12 D1 (n=10, 17)33.33 ± 27.2227.45 ± 33.82
Other pain: C13 D1 (n=8, 14)29.17 ± 27.8226.19 ± 29.75
Other pain: EOT (n=25, 37)34.67 ± 32.6029.73 ± 36.67
Medicine for pain: Baseline (n=37, 35)60.36 ± 29.2366.67 ± 28.01
Medicine for pain: C3 D1 (n=29, 24)65.52 ± 31.4868.06 ± 31.82
Medicine for pain: C4 D1 (n=19, 29)63.16 ± 26.9872.41 ± 23.69
Medicine for pain: C5 D1 (n=17, 22)70.59 ± 26.0472.73 ± 22.15
Medicine for pain: C6 D1 (n=16, 17)66.67 ± 29.8172.55 ± 24.25
Medicine for pain: C7 D1 (n=15, 14)75.56 ± 26.6366.67 ± 29.24
Medicine for pain: C8 D1 (n=13, 16)66.67 ± 27.2275.00 ± 25.82
Medicine for pain: C9 D1 (n=6, 14)72.23 ± 13.6169.05 ± 20.52
Medicine for pain: C10 D1 (n=10, 10)73.34 ± 14.0560.00 ± 26.30
Medicine for pain: C11 D1 (n=9, 9)48.15 ± 17.5781.48 ± 17.57
Medicine for pain: C12 D1 (n=6, 9)55.56 ± 17.2270.37 ± 20.03
Medicine for pain: C13 D1 (n=0, 0)NA ± NANA ± NA
Medicine for pain: EOT (n=15, 19)60.00 ± 22.5466.67 ± 29.40
Medicine for pain: C2 D1 (n=30, 35)62.22 ± 22.7271.43 ± 26.99
SecondaryPercentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood

RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.

Time frame:
Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1

No measurements were reported for this outcome.

SecondaryCirculating Endothelial Cells (CEC) in Blood: Total CEC

Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.

Time frame:
Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1
Reported as:
Mean · Cells/milliliter (cells/mL)
Circulating Endothelial Cells (CEC) in Blood: Total CEC
Cells/milliliter (cells/mL)Axitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Baseline (n=39, 37)46815.38 ± 131531.75516960.41 ± 25527.526
C1 D15 (n=27, 29)11780.15 ± 13127.84721882.41 ± 67578.781
C2 D1 (n=32, 28)29229.09 ± 55724.99740507.36 ± 82161.060
C3 D1 (n=24, 30)19517.50 ± 19793.72225215.70 ± 42932.747
C4 D1 (n=20, 27)24556.05 ± 22434.01141944.59 ± 70239.938
C5 D1 (n=18, 23)28266.22 ± 39480.20937468.13 ± 82647.380
C7 D1 (n=11, 14)71770.91 ± 94182.03236964.36 ± 60577.084
C9 D1 (n=7, 7)58680.00 ± 78138.794107978.14 ± 206314.489
C11 D1 (n=6, 6)116620.83 ± 129577.280120847.67 ± 140674.394
SecondaryCirculating Endothelial Cells (CEC) in Blood

Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.

Time frame:
Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1
Reported as:
Mean · Flourescent Intensity Unit (FIU)
Circulating Endothelial Cells (CEC) in Blood
Flourescent Intensity Unit (FIU)Axitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Baseline (pVEGFR2+) (n=50, 42)1936317.98 ± 1252665.9001764577.67 ± 1331540.549
C1 D15 (pVEGFR2+) (n=38, 37)1822095.74 ± 1678888.1531810049.32 ± 1330590.809
C2 D1 (pVEGFR2+) (n=41, 35)1767065.44 ± 1442193.2132090673.60 ± 1659128.892
C3 D1 (pVEGFR2+) (n=33, 34)1715569.39 ± 1515661.6621578940.53 ± 1274415.109
C4 D1 (pVEGFR2+) (n=25, 32)1472447.68 ± 970463.3411815402.16 ± 1263516.725
C5 D1 (pVEGFR2+) (n=24, 26)2208801.96 ± 3098289.4001794843.58 ± 1458412.725
C7 D1 (pVEGFR2+) (n=16, 16)1405048.00 ± 879770.8931634128.00 ± 1443612.089
C9 D1 (pVEGFR2+) (n=12, 11)2280989.75 ± 1050678.8082283985.00 ± 1093158.760
C11 D1 (pVEGFR2+) (n=10, 9)1828224.90 ± 1179020.4902354939.11 ± 1116283.011
Baseline (VEGFR2+) (n=50, 42)1694522.56 ± 1534520.5041841618.36 ± 1300088.201
C1 D15 (VEGFR2+) (n=38, 37)1634956.89 ± 1285333.2481740268.05 ± 1444881.394
C2 D1 (VEGFR2+) (n=41, 35)1597041.59 ± 865675.1231444404.94 ± 1097875.465
C3 D1 (VEGFR2+) (n=33, 34)1443986.61 ± 843071.9091504595.71 ± 1163469.112
C4 D1 (VEGFR2+) (n=25, 32)1181666.88 ± 673860.4071259913.44 ± 765707.741
C5 D1 (VEGFR2+) (n=24, 25)1371956.00 ± 948166.9421447188.88 ± 885864.695
C7 D1 (VEGFR2+) (n=16, 16)1028231.44 ± 495059.3781317560.13 ± 720095.027
C9 D1 (VEGFR2+) (n=12, 11)1485819.58 ± 953884.2881476621.00 ± 1688887.819
C11 D1 (VEGFR2+) (n=10, 9)1573298.80 ± 1152155.9931332064.78 ± 668964.428
Baseline (pPDGFRB+) (n=50, 42)1646702.34 ± 1482336.2441734853.24 ± 1485338.326
C1 D15 (pPDGFRB+) (n=38, 37)1253893.97 ± 894629.2981599671.65 ± 1669690.889
C2 D1 (pPDGFRB+) (n=41, 35)1395311.88 ± 1111766.4541885684.31 ± 1356916.305
C3 D1 (pPDGFRB+) (n=33, 34)1470448.94 ± 841336.3981285439.44 ± 1083860.541
C4 D1 (pPDGFRB+) (n=25, 32)1046445.72 ± 588769.3751514713.97 ± 1150805.007
C5 D1 (pPDGFRB+) (n=24, 26)2253114.67 ± 3314986.5692299459.38 ± 5140939.706
C7 D1 (pPDGFRB+) (n=16, 16)1380133.19 ± 1002147.8262163313.88 ± 3720352.717
C9 D1 (pPDGFRB+) (n=12, 11)2172539.75 ± 2323386.0872225289.18 ± 1126401.528
C11 D1 (pPDGFRB+) (n=10, 9)1580028.90 ± 927582.3643127640.22 ± 2817719.865
Baseline (PDGFRB+) (n=50, 42)1775826.12 ± 1485762.5403176459.69 ± 3222201.986
C1 D15 (PDGFRB+) (n=38, 37)1589914.37 ± 985828.9391819988.05 ± 1807664.991
C2 D1 (PDGFRB+) (n=41, 35)1840677.73 ± 1315688.8061586256.17 ± 1092406.544
C3 D1 (PDGFRB+) (n=33, 34)1690163.33 ± 1064816.0341518360.71 ± 1286285.813
C4 D1 (PDGFRB+) (n=25, 32)1288624.64 ± 641546.2541408366.91 ± 1013859.813
C5 D1 (PDGFRB+) (n=24, 26)1309639.50 ± 975890.5571364500.50 ± 1058758.211
C7 D1 (PDGFRB+) (n=16, 16)1049351.00 ± 587546.1391287039.25 ± 922009.811
C9 D1 (PDGFRB+) (n=12, 11)1666413.67 ± 1465165.3251625161.64 ± 1467355.491
C11 D1 (PDGFRB+) (n=10, 9)1533606.00 ± 1258733.5011959067.11 ± 1973194.943
SecondaryPlasma Concentration of Soluble Proteins

Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor \[VEGF\], and vascular endothelial growth factor receptor-2 \[VEGFR2\], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.

Time frame:
Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1
Reported as:
Mean · Picogram/mL (pg/mL)
Plasma Concentration of Soluble Proteins
Picogram/mL (pg/mL)Axitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Baseline (SKIT) (n=52, 47)49740.29 ± 16998.6949544.15 ± 14803.62
C1 D15 (SKIT) (n=42, 36)53095.48 ± 18233.8555801.39 ± 22058.63
C2 D1 (SKIT) (n=41, 43)52979.39 ± 18018.7355729.65 ± 21476.66
C3 D1 (SKIT) (n=40, 38)53817.75 ± 19638.7265634.14 ± 27097.91
C4 D1 (SKIT) (n=32, 38)56961.41 ± 20828.0772671.32 ± 33207.22
C5 D1 (SKIT) (n=27, 34)58305.00 ± 20311.8568677.21 ± 30073.83
C7 D1 (SKIT) (n=18, 23)50701.11 ± 17927.9875547.61 ± 24458.54
C9 D1 (SKIT) (n=12, 16)48680.42 ± 14791.3265990.78 ± 17003.08
C11 D1 (SKIT) (n=11, 13)49251.82 ± 19469.4566920.38 ± 12261.25
Baseline (VEGF) (n=50, 48)95.14 ± 66.60121.83 ± 141.22
C1 D15 (VEGF) (n=40, 37)117.08 ± 98.05287.19 ± 171.77
C2 D1 (VEGF) (n=39, 43)127.46 ± 128.06324.33 ± 153.65
C3 D1 (VEGF) (n=39, 38)148.06 ± 159.80368.23 ± 151.20
C4 D1 (VEGF) (n=30, 38)197.16 ± 282.49405.13 ± 173.86
C5 D1 (VEGF) (n=25, 34)184.77 ± 175.32400.16 ± 165.69
C7 D1 (VEGF) (n=18, 23)226.62 ± 202.53433.30 ± 172.14
C9 D1 (VEGF) (n=12, 16)273.17 ± 207.22422.38 ± 157.76
C11 D1 (VEGF) (n=11, 13)339.86 ± 303.71449.92 ± 144.50
Baseline (VEGFR2) (n=52, 48)9587.31 ± 1570.279995.00 ± 2185.61
C1 D15 (VEGFR2) (n=42, 37)7828.10 ± 1959.3910781.35 ± 2311.90
C2 D1 (VEGFR2) (n=41, 43)7477.80 ± 2146.8910330.00 ± 2511.23
C3 D1 (VEGFR2) (n=40, 38)7058.50 ± 2037.1210129.47 ± 2244.65
C4 D1 (VEGFR2) (n=32, 38)6885.94 ± 1754.199934.21 ± 1785.78
C5 D1 (VEGFR2) (n=27, 34)6565.93 ± 1755.7510140.59 ± 2056.40
C7 D1 (VEGFR2) (n=18, 23)6401.11 ± 2360.2410339.57 ± 1897.95
C9 D1 (VEGFR2) (n=12, 16)6291.67 ± 2235.249421.25 ± 2446.42
C11 D1 (VEGFR2) (n=11, 13)5696.36 ± 2724.579222.31 ± 2727.04
Baseline (VEGFR3) (n=52, 48)44390.77 ± 75118.1724718.33 ± 12494.07
C1 D15 (VEGFR3) (n=42, 37)33684.29 ± 52617.0217693.51 ± 9679.53
C2 D1 (VEGFR3) (n=41, 43)35780.49 ± 68287.6817798.37 ± 9710.23
C3 D1 (VEGFR3) (n=40, 38)34147.00 ± 74220.3015901.32 ± 8062.41
C4 D1 (VEGFR3) (n=32, 38)19730.94 ± 9237.6916307.37 ± 7409.61
C5 D1 (VEGFR3) (n=27, 34)17452.59 ± 8614.9916381.47 ± 6707.41
C7 D1 (VEGFR3) (n=18, 23)17896.67 ± 8360.8215626.30 ± 8873.31
C9 D1 (VEGFR3) (n=12, 16)21449.17 ± 12806.7514733.44 ± 6441.61
C11 D1 (VEGFR3) (n=11, 13)22332.73 ± 12408.3716048.46 ± 7064.47
Other pre-specifiedPlasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype

UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.

Time frame:
Baseline (Day 1 of Cycle 1)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Paclitaxel + Carboplatin—31/58 (53.4%)54/58 (93.1%)
Bevacizumab + Paclitaxel + Carboplatin—19/59 (32.2%)58/59 (98.3%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Disease progressionGeneral disorders7/583/59
DehydrationMetabolism and nutrition disorders4/580/59
AstheniaGeneral disorders3/580/59
Myocardial infarctionCardiac disorders2/580/59
SepsisInfections and infestations2/580/59
NeutropeniaBlood and lymphatic system disorders1/582/59
OesophagitisGastrointestinal disorders0/582/59
FatigueGeneral disorders1/582/59
Lower respiratory tract infectionInfections and infestations0/582/59
AnaemiaBlood and lymphatic system disorders1/580/59
Most frequent other events
Showing 10 of 68
Most frequent other events
EventAxitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
DiarrhoeaGastrointestinal disorders27/5820/59
AlopeciaSkin and subcutaneous tissue disorders21/5827/59
Decreased appetiteMetabolism and nutrition disorders25/5812/59
HypertensionVascular disorders24/5825/59
FatigueGeneral disorders20/5822/59
NauseaGastrointestinal disorders21/5819/59
NeutropeniaBlood and lymphatic system disorders18/5815/59
AstheniaGeneral disorders17/586/59
DyspnoeaRespiratory, thoracic and mediastinal disorders17/5815/59
ConstipationGastrointestinal disorders16/5817/59

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.

Age, Customized
Age, Customized(Participants)Axitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + CarboplatinTotal
Less than 18 years000
18 to 44 years123
45 to 64 years334477
Greater than or equal to 65 years241438
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + CarboplatinTotal
Female222345
Male363773
08

Study locations

44 sites
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Pfizer Investigational Site
    Pittsfield, Massachusetts 01201, United States
  • Pfizer Investigational Site
    Columbus, Mississippi 39705, United States
  • Pfizer Investigational Site
    Corinth, Mississippi 38834, United States
  • Pfizer Investigational Site
    New Albany, Mississippi 38652, United States
  • Pfizer Investigational Site
    Oxford, Mississippi 38655, United States
  • Pfizer Investigational Site
    Southaven, Mississippi 38671, United States
  • Pfizer Investigational Site
    Tupelo, Mississippi 38801, United States
  • Pfizer Investigational Site
    Lincoln, Nebraska 68510, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44109, United States
  • Pfizer Investigational Site
    Bartlett, Tennessee 38133, United States
  • Pfizer Investigational Site
    Germantown, Tennessee 38138, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38119, United States
  • Pfizer Investigational Site
    Memphis, Tennessee 38120, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    Dallas, Texas 75390-8590, United States
  • Pfizer Investigational Site
    Lubbock, Texas 79410, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78284, United States
  • Pfizer Investigational Site
    Wenatchee, Washington 98801, United States
  • Pfizer Investigational Site
    Praha 8, 180 81, Czech Republic
  • Pfizer Investigational Site
    Tabor, 390 03, Czech Republic
  • Pfizer Investigational Site
    Usti nad Labem, 401 13, Czech Republic
  • Pfizer Investigational Site
    Caen Cedex 05, 14076, France
  • Pfizer Investigational Site
    Paris Cedex 14, 75679, France
  • Pfizer Investigational Site
    Pierre-Bénite, 69495, France
  • Pfizer Investigational Site
    Bydgoszcz, 85-796, Poland
  • Pfizer Investigational Site
    Gdansk, 80-462, Poland
  • Pfizer Investigational Site
    Gdynia, 81-519, Poland
  • Pfizer Investigational Site
    Torun, 87 - 100, Poland
  • Pfizer Investigational Site
    Warszawa, 02-097, Poland
  • Pfizer Investigational Site
    Mataro, Barcelona 08304, Spain
  • Pfizer Investigational Site
    Sabadell, Barcelona 08208, Spain
  • Pfizer Investigational Site
    Alicante, 03010, Spain
  • Pfizer Investigational Site
    Valencia, 46014, Spain
  • Pfizer Investigational Site
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Pfizer Investigational Site
    Dundee, Scotland DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Leeds, Yorkshire LS9 7TF, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    London, NW1 2PG, United Kingdom
  • Pfizer Investigational Site
    London, SW3 6JJ, United Kingdom
  • Pfizer Investigational Site
    Surrey, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489. PubMed 24356624 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Apr 2011 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 1 month after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2008
First posted
Jan 25, 2008
Start
Apr 2008
Primary completionActual
Apr 2011
CompletionActual
Oct 2012
Results delay requested
Feb 11, 2010
Results first posted
May 22, 2012
Last update
Nov 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00600821
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 25, 2008
Start date
Apr 2008
Primary completion
Apr 2011
Completion
Oct 2012
Results posted
May 22, 2012
Last update
Nov 8, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion